Advertisement

Topics

Prostate Brachytherapy Advisory Group Company Profile

17:06 EST 22nd November 2017 | BioPortfolio

SOURCE Prostate Brachytherapy Advisory Group


News Articles [1270 Associated News Articles listed on BioPortfolio]

Prostate cancer: Brachytherapy monotherapy is efficacious

Global Brachytherapy Afterloaders, Brachytherapy Seeds Market Data Survey Report 2025 [Report Updated: 07082017] Prices from USD $1500

SummaryBrachytherapy also known as internal radiotherapy, sealed source radiotherapy, curie therapy or endocurietherapy, is a form of radiotherapy where a sealed radiation source is placed inside or n...

No difference in toxicity for 6-, 2-fraction HDR in prostate cancer

(HealthDay)—For men with prostate cancer there is no difference in acute genitourinary or sexual dysfunction between 6- and 2-fraction high-dose-rate (HDR) brachytherapy monotherapy, according to a ...

C4 Imaging Announces an Additional FDA 510(k) Clearance for its Positive-Signal MRI Marker - Sirius™

HOUSTON, Sept. 5, 2017 /PRNewswire/ -- C4 Imaging LLC is pleased to announce an additional US Food and Drug Administration 510(k) clearance for its Sirius™ MRI Marker, a novel positive-signal M...

Global Brachytherapy Afterloaders, Brachytherapy Seeds Market Analysis 20112017 and Forecast 20182023 [Report Updated: 17032017] Prices from USD $2980

SnapshotBrachytherapy also known as internal radiotherapy, sealed source radiotherapy, curie therapy or endocurietherapy, is a form of radiotherapy where a sealed radiation source is placed inside or ...

Global Brachytherapy Afterloaders Market Data Survey Report 2025 [Report Updated: 07082017] Prices from USD $1500

SummaryBrachytherapy also known as internal radiotherapy, sealed source radiotherapy, curie therapy or endocurietherapy, is a form of radiotherapy where a sealed radiation source is placed inside or n...

IsoRay Medical Release: New Study Shows Brachytherapy And Cesium-131 Isotope Treatment Beneficial For Prostate Cancer Patients

  Life Sciences Jobs   ...

Global Brachytherapy Afterloaders Market Analysis 20112017 and Forecast 20182023 [Report Updated: 16032017] Prices from USD $2980

SnapshotBrachytherapy also known as internal radiotherapy, sealed source radiotherapy, curie therapy or endocurietherapy, is a form of radiotherapy where a sealed radiation source is placed inside or ...

Drugs and Medications [229 Associated Drugs and Medications listed on BioPortfolio]

Angiomax [The Medicines Company]

These highlights do not include all the information needed to use ANGIOMAX safely and effectively. See full prescribing information for ANGIOMAX. ANGIOMAX (bivalirudin) for injection, for intravenous ...

Angiomax [Cardinal Health]

These highlights do not include all the information needed to use ANGIOMAX safely and effectively. See full prescribing information for ANGIOMAX. ANGIOMAX (bivalirudin) for injection, for intravenous ...

Doxazosin [Apotex Corp.]

DOXAZOSIN TABLETS, USP 1 mg, 2 mg, 4 mg and 8 mg

Doxazosin mesylate tablets 1 mg, 2 mg, 4 mg, 8 mg (doxazosin) [Genpharm Inc.]

DOXAZOSIN MESYLATE TABLETS 1 mg, 2 mg, 4 mg, 8 mg (doxazosin)

Doxazosin mesylate tablets 40-8835 revised — october 2003 [Actavis Elizabeth LLC]

DOXAZOSIN MESYLATE TABLETS 40-8835 Revised — October 2003

PubMed Articles [2998 Associated PubMed Articles listed on BioPortfolio]

Permanent prostate brachytherapy pubic arch evaluation with diagnostic MRI.

Pubic arch interference (PAI), when it occurs, is often a limiting factor for patients pursuing brachytherapy treatment of prostate cancer. Pre-brachytherapy pubic arch evaluation is often performed b...

A novel urethral sparing technique for high-dose-rate prostate brachytherapy after transurethral resection of the prostate.

The purpose of this study was to assess retrospectively the variability of the urethral dose optimized using a Foley catheter versus urethral contrast injected using a new modified triple-lumen cathet...

Low dose-rate contact radiation therapy (brachytherapy) for prostate cancer using domestic I-125 seeds as a monotherapy and combined with pelvic lymphadenectomy.

In 2014, the incidence of prostate cancer in the Russian Federation was 116.4 per 100,000 population. It is noteworthy that from 2004 to 2014, the proportion of patients with stage I-II prostate cance...

Multisource Rotating Shield Brachytherapy Apparatus for Prostate Cancer.

Our purpose is to present a novel multisource rotating shield brachytherapy (RSBT) apparatus for the simultaneous precise angular and linear positioning of partially shielded (153)Gd brachytherapy sou...

Manual vs. automated implantation of seeds in prostate brachytherapy: Oncologic results from a single-center study.

The objective of this study was to study survival and tolerance of prostate cancer patients treated with (125)I permanent interstitial brachytherapy by automated vs. manual implantation of seeds.

Clinical Trials [5279 Associated Clinical Trials listed on BioPortfolio]

Seizure Advisory System Feasibility Study

The purpose of this prospective, single-arm, unblinded, multicenter clinical study is to evaluate the safety and effectiveness of the NeuroVista Seizure Advisory System (SAS) in patients w...

Assessment of Bone Loss in Men Receiving Treatment for Prostate Cancer

The ANTELOPE trial is a longitudinal observational clinical study of changes in bone density, structure and strength over 12 months in men receiving treatment for prostate cancer. Three gr...

Androgen Deprivation Therapy (ADT) Versus ADT Plus Prostate Cryotherapy for Metastatic Prostate Cancer (mPCa)

Patients with primary diagnosed metastatic prostate cancer are randomly divided into two groups. One group receive standard of care ADT continually. Another group receive ADT plus prostate...

The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer

The IMPACT study is an international targeted prostate screening study of men at increased prostate cancer risk due to the presence of known pathogenic mutations in BRCA1 and BRCA2 genes. ...

Living With Prostate Cancer (LPC)

This is a prospective evaluation to determine the effectiveness of the Prostate Cancer Supportive Care (PCSC) Program's group therapy program, Living with Prostate Cancer (LPC). LPC is an ...

Companies [2127 Associated Companies listed on BioPortfolio]

Prostate Brachytherapy Advisory Group

SOURCE Prostate Brachytherapy Advisory Group

IsoRay Inc.

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of the Cesium-131 brachytherapy seed, used to treat prostate and other cancers. The Cesium-131 see...

GammaWest Brachytherapy

Brachytherapy is an advanced cancer treatment. The word "brachy" is Greek for "close by" and refers to placing radioactive seeds or sources directly in the tumor. This procedure gives physicians and p...

CET CANCER CENTER

California Endocurietherapy Cancer Center (CET) is the first brachytherapy only center in the United States.Founded by D Jeffrey Demanes M.D. in 1981.Dedicated solely to High Dose Rate brachytherapy (...

Oncura

On July 1, 2003, a merger between two innovative leaders in prostate cancer treatments set the standard for minimally invasive options. The merger between Amersham Health (now GE Healthcare)–Therapy...

More Information about "Prostate Brachytherapy Advisory Group" on BioPortfolio

We have published hundreds of Prostate Brachytherapy Advisory Group news stories on BioPortfolio along with dozens of Prostate Brachytherapy Advisory Group Clinical Trials and PubMed Articles about Prostate Brachytherapy Advisory Group for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Prostate Brachytherapy Advisory Group Companies in our database. You can also find out about relevant Prostate Brachytherapy Advisory Group Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record